《瑞銀窩輪》藥明旗下兩家子公司被美剔出未經核實名單 看好留意藥明牛證(58220)
港股上週五隨美股低開,早市曾有報道指香港與內地預計將於下月全面通關,利好消息刺激令大市轉跌為升,其後升勢回順,最後週五收市報19450,失守19500點關口。12月16日恆指升82.08點,大市成交金額1360億港元,全日波幅約491點。
個股方面,早上有消息傳出美國商務部決定將藥明生物(02269)旗下兩家子公司(無錫藥明生物技術及上海藥明生物技術) 剔出未經核實名單,此利好消息令藥明(2269) 週五曾升逾7.5%。而根據港股通(滬)資金流顯示,上週四北水亦有流入藥明。如投資者看好藥明,可留意藥明認購(27127),行使價53.93港元,23年5月到期,有效槓桿約3.4倍。如想避免引伸波幅回調,亦可考慮用牛熊證部署。如投資者看好藥明,可留意藥明牛證(58220),收回價40港元,23年5月到期,有效槓桿約3.7倍。 如認為市場消化此消息後,近10天線大概$52.2附近會有阻力,如投資者看淡藥明,可留意藥明熊證(69739),收回價60港元,23年6月到期,有效槓桿約5.1倍。
另外,吉利汽車(00175) 旗下電動車品牌「極氪(Zeekr)」公布完成此前定下的7萬輛全年交付目標。於是吉利上週五亦升3%,如投資者看好吉利,可留意吉利認購(15926),行使價13.52港元,23年3月到期,有效槓桿約5.2倍。
更多窩輪牛熊資訊:瑞銀認股證牛熊證網站: http://www.ubs.com/hkwarrants
輪證教學及巿況焦點短片:
https://www.youtube.com/channel/UCKw86qy4eBAInmd52MND45Q?view_as=subscriber
瑞銀認股證牛熊證團隊
本產品並無抵押品。 如發行人無力償債或違約,投資者可能無法收回部份或全部應收款項。筆者為UBS AG的代表(作為證監會持牌人),並未持有相關上市公司的任何財務權益。本資料由瑞銀刊發,其並不構成買賣建議、邀請、要約或遊說。結構性產品價格可急升或急跌,投資者可能會蒙受全盤損失。過往表現並不反映將來表現。牛熊證備強制贖回機制而可能被提早終止,屆時 (i) N類牛熊證投資者將不獲發任何金額;而(ii) R類牛熊證之剩餘價值可能為零。投資前應瞭解有關風險,並諮詢專業顧問及查閱有關上市檔。UBS Securities Hong Kong Limited為結構性產品之流通量提供者,亦可能是唯一報價者或巿場參與者。(C) UBS 2022。版權所有。~
重要聲明:
以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.